Outlook Therapeutics names Kevin Lundquist CFO, replacing Lawrence Kenyon
OTLK•Current CFO transition
Lawrence Kenyon will step down as CFO on Sept. 1, 2026, staying as a non-executive employee through Sept. 30, 2026.
New chief financial officer appointment
Outlook Therapeutics named Kevin Lundquist chief financial officer, effective Sept. 1, 2026.
Lundquist previously served as CFO of CapsoVision, overseeing finance and operations through its 2025 IPO process.
Earlier roles include CFO of Abzena Biologics, VP of finance at Revance Therapeutics, finance leadership at Genentech/Roche.
